UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Apr

    10

    UCB Launches Make HStory, an Educational Campaign Offering Resources and Support for Those Living with Hidradenitis Suppurativa

    Read More Share:linkedin| twitter| email| facebook

    Apr

    04

    FDA Accepts Supplemental Biologics License Applications for BIMZELX® (bimekizumab-bkzx) for Moderate-to-Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

    Read More Share:linkedin| twitter| email| facebook

    Mar

    09

    First Presentation of Year 4 BIMZELX® (bimekizumab-bkzx) Data Showed Long-Term Maintenance of Complete Skin Clearance in Moderate-to-Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email| facebook

    Mar

    08

    BIMZELX® 48-Week Phase 3 Analyses in Moderate-to-Severe Hidradenitis Suppurativa Showed Sustained Improvements in Skin Pain and Draining Tunnel Count

    Read More Share:linkedin| twitter| email| facebook

    Jan

    11

    Our Wish in 2024: Renewed Hope for People Living with Chronic Inflammatory Diseases

    Read More Share:linkedin| twitter| email| facebook

    Oct

    18

    BIMZELX® Approved by the U.S. FDA for the Treatment of Adults with Moderate-to-Severe Plaque Psoriasis

    Read More Share:linkedin| twitter| email| facebook

    Mar

    26

    New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

    Read More Share:linkedin| twitter| email| facebook

    Dec

    16

    Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

    Read More Share:linkedin| twitter| email| facebook

    Oct

    22

    UCB Presents Number Needed to Treat Analysis for Bimekizumab in Moderate to Severe Plaque Psoriasis at AMCP Nexus

    UCB today announced new data from a network meta-analysis (NMA) demonstrating that bimekizumab was associated with the lowest number needed to treat (NNT) to achieve Psoriasis Area and Severity Index (PASI) 90 and PASI 100 skin clearance levels compared with 12 other approved biologic therapies used for moderate to severe plaque psoriasis within 16 weeks. These results were presented at the Academy of Managed Care Pharmacy (AMCP) Nexus 2021, October 18-21. 

    Read More Share:linkedin| twitter| email| facebook

    Oct

    16

    Update on U.S. FDA Review of Biologics License Application (BLA) for bimekizumab

    Read More Share:linkedin| twitter| email| facebook

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)